Hohimer Wealth Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-47,328
Closed -$1.31M 249
2024
Q1
$1.31M Buy
47,328
+2,278
+5% +$63.2K 0.31% 90
2023
Q4
$1.3M Sell
45,050
-60,250
-57% -$1.82M 0.33% 85
2023
Q3
$3.49M Sell
105,300
-2,614
-2% -$92.4K 1% 30
2023
Q2
$3.96M Sell
107,914
-2,082
-2% -$81K 1.09% 22
2023
Q1
$4.49M Buy
109,996
+40,319
+58% +$1.74M 1.3% 14
2022
Q4
$3.57M Sell
69,677
-2,773
-4% -$133K 1.14% 26
2022
Q3
$3.17M Buy
72,450
+1,014
+1% +$49.3K 1.02% 34
2022
Q2
$3.75M Sell
71,436
-30,010
-30% -$1.53M 1.11% 17
2022
Q1
$5.25M Buy
101,446
+4,234
+4% +$220K 1.04% 23
2021
Q4
$5.74M Sell
97,212
-8,066
-8% -$400K 1.21% 18
2021
Q3
$4.53M Sell
105,278
-3,032
-3% -$134K 0.95% 27
2021
Q2
$4.24M Buy
108,310
+7,133
+7% +$277K 0.87% 37
2021
Q1
$3.67M Buy
101,177
+9,296
+10% +$330K 0.89% 33
2020
Q4
$3.38M Buy
91,881
+38,378
+72% +$1.41M 0.9% 29
2020
Q3
$1.92M Buy
53,503
+96
+0.2% +$3.37K 0.55% 60
2020
Q2
$1.66M Sell
53,407
-720
-1% -$24.5K 0.57% 59
2020
Q1
$1.97M Buy
54,127
+18,967
+54% +$646K 0.83% 40
2019
Q4
$1.31M Buy
+35,160
New +$1.25M 0.45% 102

Other funds holding PFE

Hohimer Wealth Management's PFE Position: Q2 2024 in Review

Hohimer Wealth Management sold out of Pfizer (PFE) in Q2 2024, closing a stake of 47,328 shares — an estimated $1.31M sold.

Hohimer Wealth Management first reported a position in PFE in Q4 2019 and held it in 18 quarters. The position peaked at $5.74M in Q4 2021. 2,873 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

  • Hohimer Wealth Management reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
  • Hohimer Wealth Management sold 47,328 Pfizer shares in Q2 2024, an estimated $1.31M.
  • Hohimer Wealth Management first reported a position in Pfizer in Q4 2019 and held it in 18 quarters.
  • Hohimer Wealth Management's Pfizer position peaked at $5.74M in Q4 2021.
  • 2,873 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Hohimer Wealth Management's 13F filing for Q2 2024, filed 2 Aug 2024.